• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by DURECT Corporation

    9/11/25 11:10:51 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    S-8 POS 1 d76401ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on September 11, 2025

    Registration No. 333-47400

    Registration No. 333-61224

    Registration No. 333-76622

    Registration No. 333-86110

    Registration No. 333-98939

    Registration No. 333-108390

    Registration No. 333-120405

    Registration No. 333-124701

    Registration No. 333-126990

    Registration No. 333-134200

    Registration No. 333-145244

    Registration No. 333-152968

    Registration No. 333-161025

    Registration No. 333-166700

    Registration No. 333-170349

    Registration No. 333-176113

    Registration No. 333-197980

    Registration No. 333-206084

    Registration No. 333-212842

    Registration No. 333-219832

    Registration No. 333-226524

    Registration No. 333-240326

    Registration No. 333-266590

    Registration No. 333-273879

    Registration No. 333-283231

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-47400

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-61224

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-76622

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-86110

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-98939

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-108390

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-120405

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-124701

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-126990

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-134200

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-145244

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-152968

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-161025

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-166700

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-170349

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-176113

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-197980

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-206084

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-212842

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-219832

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-226524

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-240326

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-266590

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-273879

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-283231

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    DURECT CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   94-3297098

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    10240 Bubb Road

    Cupertino, CA 95014

    (408) 777-1417

    (Address of Principal Executive Offices) (Zip Code)

     

     

    SOUTHERN BIOSYSTEMS, INC. 1993 STOCK OPTION PLAN

    SOUTHERN RESEARCH TECHNOLOGIES, INC. 1995 NONQUALIFIED STOCK OPTION PLAN

    DURECT CORPORATION 1998 INCENTIVE STOCK PLAN

    DURECT CORPORATION 2000 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED

    DURECT CORPORATION 2000 STOCK PLAN, AS AMENDED

    DURECT CORPORATION 2000 DIRECTORS’ STOCK OPTION PLAN

    (Full titles of the plans)

    Timothy M. Papp

    Chief Financial Officer

    DURECT Corporation

    10240 Bubb Road

    Cupertino, CA 95014

    (408) 777-1417

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Alison S. Ressler

    Sullivan & Cromwell LLP

    1888 Century Park East

    Los Angeles, CA 90067-1725

    Telephone: (310) 712-6630

    Scott B. Crofton

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, NY 10004-2498

    Telephone: (212) 558-4682

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”), filed by DURECT Corporation, a Delaware corporation (the “Company”), remove from registration all shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) previously registered under the following Registration Statements on Form S-8 filed by the Company (the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”) pertaining to the registration of shares of Common Stock.

     

      •  

    Registration No. 333-47400, which was previously filed with the SEC on October 5, 2000, registering 325,750 shares of Common Stock under the 1998 Incentive Stock Plan, 150,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended, 1,179,800 shares of Common Stock under the 2000 Stock Plan, as amended and 300,000 shares of Common Stock under the 2000 Directors’ Stock Option Plan;

     

      •  

    Registration No. 333-61224, which was previously filed with the SEC on May 18, 2001, registering 462,713 shares of Common Stock under the Southern BioSystems, Inc. 1993 Stock Option Plan, 170,207 shares of Common Stock under the Southern Research Technologies, Inc. 1995 Nonqualified Stock Option Plan, 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-76622, which was previously filed with the SEC on January 11, 2002, registering 118,396 shares of Common Stock under the Southern BioSystems, Inc. 1993 Stock Option Plan and 73,402 shares of Common Stock under the Southern Research Technologies, Inc. 1995 Nonqualified Stock Option Plan;

     

      •  

    Registration No. 333-86110, which was previously filed with the SEC on April 12, 2002, registering 225,000 shares under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-98939, which was previously filed with the SEC on August 29, 2002, registering 200,000 shares of Common Stock under the 2000 Directors’ Stock Option Plan;

     

      •  

    Registration No. 333-108390, which was previously filed with the SEC on August 29, 2003, registering 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-120405, which was previously filed with the SEC on November 12, 2004, registering 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-124701, which was previously filed with the SEC on May 6, 2005, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-126990, which was previously filed with the SEC on July 28, 2005, registering 425,000 shares of Common Stock under the 2000 Directors’ Stock Option Plan;

     

      •  

    Registration No. 333-134200, which was previously filed with the SEC on May 17, 2006, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-145244, which was previously filed with the SEC on August 8, 2007, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-152968, which was previously filed with the SEC on August 12, 2008, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-161025, which was previously filed with the SEC on August 4, 2009, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;


      •  

    Registration No. 333-166700, which was previously filed with the SEC on May 10, 2010, registering 225,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended and 2,250,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-170349, which was previously filed with the SEC on November 4, 2010, registering 250,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration No. 333-176113, which was previously filed with the SEC on August 5, 2011, registering 5,500,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-197980, which was previously filed with the SEC on August 8, 2014, 4,000,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-206084, which was previously filed with the SEC on August 4, 2015, registering 350,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration No. 333-212842, which was previously filed with the SEC on August 2, 2016, registering 5,000,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-219832, which was previously filed with the SEC on August 9, 2017, registering 350,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration No. 333-226524, which was previously filed with the SEC on August 2, 2018, registering 7,500,000 shares of Common Stock under the 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-240326, which was previously filed with the SEC on August 4, 2020, registering 350,000 shares of Common Stock under the 2000 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration No. 333-266590, which was previously filed with the SEC on August 5, 2022, registering 18,000,000 shares of Common Stock under 2000 Stock Plan, as amended;

     

      •  

    Registration No. 333-273879, which was previously filed with the SEC on August 10, 2023, registering 40,000 shares of Common Stock (after giving effect to the 1-for-10 reverse stock split of the Common Stock occurring on December 5, 2022) under the 2000 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration No. 333-283231, which was previously filed with the SEC on November 14, 2024, registering 2,000,000 shares of Common Stock (after giving effect to the 1-for-10 reverse stock split of the Common Stock occurring on December 5, 2022) under 2000 Stock Plan, as amended;

    The number of shares of Common Stock registered under the Registration Statements set forth above that were filed prior to December 5, 2022 have not been adjusted to reflect the 1-for-10 reverse stock split of the issued and outstanding shares of Common Stock effected by the Company on December 5, 2022.

    On July 28, 2025, the Company entered into an Agreement and Plan of Merger (as amended from time to time, the “Merger Agreement”) with Bausch Health Americas, Inc., a Delaware corporation (“Parent”), BHC Lyon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and solely for purposes of Section 6.10 thereof, Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia. On September 11, 2025, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”).


    As a result of the Merger, the Company has terminated all offerings of the Company’s securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all plan interests and any and all securities registered for issuance under the Registration Statements that remain unsold as of the date hereof. This filing is made in accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance that remain unsold at the termination of the offering.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cupertino, State of California on September 11, 2025.

     

    DURECT CORPORATION
    By:   /s/ Timothy M. Papp
      Name: Timothy M. Papp
      Title: Chief Financial Officer

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $DRRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by President & CEO Brown James E

    4/A - DURECT CORP (0001082038) (Issuer)

    9/16/25 2:16:30 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Robertson Judith J. closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 9:34:05 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Brown James E returned 96,959 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 8:47:03 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

    Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the second quarter ended June 30, 2025 and provided an update on the previously announced acquisition of DURECT by Bausch Health Companies Inc. (Bausch Health). Recent business highlights and updates: In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with Bausch Health America

    8/12/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

    Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

    5/13/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    SEC Filings

    View All

    SEC Form 15-12G filed by DURECT Corporation

    15-12G - DURECT CORP (0001082038) (Filer)

    9/22/25 6:36:16 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by DURECT Corporation

    EFFECT - DURECT CORP (0001082038) (Filer)

    9/15/25 12:15:04 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by DURECT Corporation

    S-8 POS - DURECT CORP (0001082038) (Filer)

    9/11/25 11:14:47 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Durect with a new price target

    HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

    5/5/21 6:31:29 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Durect with a new price target

    Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    2/3/21 8:15:53 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $DRRX
    Financials

    Live finance-specific insights

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    3/27/24 3:15:14 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    2/16/24 4:09:22 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    3/19/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

    -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

    11/13/24 4:01:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    View All

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

    CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

    3/21/23 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

    CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

    7/5/22 8:30:00 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care